Nov 13, 2026 This Week in Cardiology

NOV 13, 202634 MIN

Description

Listener feedback on the PROGRESS trial, the first Factor XI inhibitor improved, left bundle branch pacing, and statin discontinuation in older adults are the topics John Mandrola, MD, discusses in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback PROGRESS Trial https://www.nejm.org/doi/abs/10.1056/NEJMoa2607326 II FDA Approves Asundexian in Stroke Will FDA-Approved Factor XIa Change Secondary Stroke Prevention? https://www.medscape.com/viewarticle/will-fda-approved-factor-xia-change-secondary-stroke-2026a100177u OCEANIC-STROKE Trial https://www.nejm.org/doi/10.1056/NEJMoa2513880 Bleeding With Asundexian vs Placebo in Patients With Ischemic Stroke or High-Risk TIA https://pubmed.ncbi.nlm.nih.gov/42866879/ OCEANIC-AF trial https://www.nejm.org/doi/full/10.1056/NEJMoa2407105 III Another Weak Pacing RCT – OptimPacing The Best Pacing Strategy for AV Block: A Head vs Heart Analysis of The OptimPacing Trial https://www.medscape.com/viewarticle/best-pacing-strategy-av-block-head-vs-heart-analysis-2026a10016rn LEAP-Block Trial https://jamanetwork.com/journals/jama/fullarticle/2855975 OptimPacing Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2612972 IV STREAM Trial Statins Work in Older Adults, Statistics Be Damned: The STREAM Trial https://www.medscape.com/viewarticle/statins-work-older-adults-statistics-be-damned-stream-trial-2026a10016oo STREAM Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2606634 STAREE Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2607314 The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact [email protected] Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.